DrugPatentWatch Database Preview
Alnylam Pharms Inc Company Profile
What is the competitive landscape for ALNYLAM PHARMS INC, and when can generic versions of ALNYLAM PHARMS INC drugs launch?
ALNYLAM PHARMS INC has one approved drug.
There are twenty-one US patents protecting ALNYLAM PHARMS INC drugs.
Summary for Alnylam Pharms Inc
| US Patents: | 21 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Alnylam Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | 8,895,721 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | 8,492,359 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | 8,822,668 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for Alnylam Pharms Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Australia | 2003248708 | ➤ Try a Free Trial |
| Spain | 2336887 | ➤ Try a Free Trial |
| Denmark | 2028278 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
